Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1992019645 - NOUVEAU POLYPEPTIDE AVEC AFFINITE POUR LES LYPOPOLYSACCHARIDES ET UTILISATIONS DE CE POLYPEPTIDE

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. A polypeptide represented by the following formula
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A1-A2-Cys-A2-A3-A3-Cys-A2-A3-Gly-A2-Cys-A2-A3-A3-Cys-A4-A5

or salt thereof in which
A1 is a hydrogen or at least one and no more than two amino acids selected from the group consisting of lysine and arginine,
A2 is a tyrosine, phenylalanine or tryptophan residue,
A3 is an arginine or lysine residue,
A4 is at least one and no more than two amino acids selected from the group consisting of lysine and arginine,
A5 is an -OH or an NH2,
Cys is a cysteine residue, and
Gly is a glycine residue.

2. The polypeptide or salt thereof of claim 1 in which A1 is a hydrogen.

3. The polypeptide or salt thereof of claim 1 in which A1 is at least one amino acid selected from the group consisting of lysine and arginine.

4. The polypeptide or salt thereof of claim 1 in which A1 is two amino acids, in which said amino acids are selected from the group consisting of lysine and arginine.

5. The polypeptide or salt thereof of claim 1 in which A4 is at least one amino acid selected from the group consisting of lysine and arginine.

6. The polypeptide or salt thereof of claim 1 in which A4 is two amino acids, in which said amino acids are selected from the group consisting of lysine and arginine.

7. The polypeptide or salt thereof of claim 1 in which the cysteine residues at the 3- and 16-positions are linked through a disulfide linkage.

8. The polypeptide or salt thereof of claim 1 in which the cysteine residues at the 7- and 12-positions are linked through a disulfide linkage.

9. A polypeptide represented by the following formula
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
A1-A2-Cys-A2-A3-A3-Cys-A2-A3-Gly-A2-Cys-A2-A3-A3-Cys-A4-A5

or salt thereof in which
A1 is a hydrogen or at least one and no more than two amino acids selected from the group consisting of lysine and arginine,
A2 is a tyrosine, phenylalanine or tryptophan residue,
A3 is an arginine or lysine residue,
A4 is at least one and no more than two amino acids selected from the group consisting of lysine and arginine,
A5 is an -OH or an -NH2,
Cys is a cysteine residue, and Gly is a glycine residue; and the cysteine residues at the 3- and 16-positions are linked through a disulfide linkage, and the cysteine residues at the 7- and 12-positions are linked through a disulfide linkage.

10. A pharmaceutical composition for inhibiting HIV activity in a patient comprising an effective amount of the polypeptide of claim 1 and a pharmaceutical carrier.

11. A pharmaceutical composition for inhibiting HIV activity in a patient comprising an effective amount of the novel polypeptide of claim 9 and a pharmaceutical carrier.